In vitro models for studying hepatitis B virus drug resistance.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Seminars in liver disease (Print)

• Publication date

  2006-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/S-2006-939759PMID 16673295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatitis B Virus: Molecular Virology and Common Mutants

  2006cited by this paper
• In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2′,3′-Dideoxy-3′-Fluoroguanosine

  2006cited by this paper
• Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities

  2005cited by this paper
• Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV

  2005cited by this paper
• Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir

  2005cited by this paper
• Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

  2005cited by this paper
• Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate

  2005cited by this paper
• Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.

  2005cited by this paper
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

  2004cited by this paper
• HIV drug resistance.

  2004cited by this paper
• Management of Antiviral Resistance in Patients with Chronic Hepatitis B

  2004cited by this paper
• Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.

  2004cited by this paper
• Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.

  2004cited by this paper
• Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

  2004cited by this paper
• In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector.

  2004cited by this paper
• A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus

  2004cited by this paper
• In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir

  2003cited by this paper
• Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.

  2003cited by this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cited by this paper
• Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.

  2003cited by this paper
• Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses

  2002cited by this paper
• Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro

  2002cited by this paper
• Inhibition of Duck Hepatitis B Virus Infection by a Myristoylated Pre-S Peptide of the Large Viral Surface Protein

  2002cited by this paper
• Infection of a human hepatoma cell line by hepatitis B virus

  2002cited by this paper
• Comparison of Sequence Analysis and the INNO-LiPA HBV DR Line Probe Assay for Detection of Lamivudine-Resistant Hepatitis B Virus Strains in Patients under Various Clinical Conditions

  2001cited by this paper
• Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

  2001cited by this paper
• Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

  2001cited by this paper
• Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing.

  2001cited by this paper
• Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.

  2001cited by this paper
• Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir

  2000cited by this paper
• In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance

  2000cited by this paper
• Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

  2000cited by this paper
• Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

  2000cited by this paper
• Characterization of Novel Human Hepatoma Cell Lines with Stable Hepatitis B Virus Secretion for Evaluating New Compounds against Lamivudine- and Penciclovir-Resistant Virus

  2000cited by this paper
• Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy

  2000cited by this paper
• Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

  2000cited by this paper
• Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA

  1999cited by this paper
• Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

  1999cited by this paper
• Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.

  1999cited by this paper
• The M539V Polymerase Variant of Human Hepatitis B Virus Demonstrates Resistance to 2′-Deoxy-3′-Thiacytidine and a Reduced Ability to Synthesize Viral DNA

  1998cited by this paper
• Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

  1998cited by this paper
• Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

  1998cited by this paper
• Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

  1998cited by this paper
• Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

  1997cited by this paper
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

  1997cited by this paper
• 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

  1996cited by this paper
• A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients

  1995cited by this paper
• Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine

  1994cited by this paper
• The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis.

  1992cited by this paper

• Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients

  2025cites this paper
• Discussion on the Attributes of Natural Biodegradant in Killing and Inhibiting Viruses

  2024cites this paper
• Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.

  2021cites this paper
• Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.

  2021cites this paper
• Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients.

  2020cites this paper
• Prevalence of the entecavir‐resistance‐inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients

  2019cites this paper
• Investigation of hepatitis B virus (HBV) rtS78T/sC69* mutation in a large cohort of chronic HBV-infected patients with nucleoside/nucleotide analogue treatment.

  2019cites this paper
• Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals

  2018cites this paper
• Hepatitis B Virus Drug Resistance

  2017cites this paper
• Emerging drugs for hepatitis

  2017cites this paper
• A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.

  2016cites this paper
• Investigation into Drug-Resistant Mutations of HBV from 845 Nucleoside/Nucleotide Analogue-Naive Chinese Patients with Chronic HBV Infection

  2015cites this paper
• Hepatitis B and D Viruses

  2015cites this paper
• Generation of a human hepatoma cell line supporting efficient replication of a lamivudine resistant hepatitis B virus.

  2014cites this paper
• A simple and efficient strategy for the de novo construction of greater-than-genome-length hepatitis B virus replicons.

  2014cites this paper
• Construction of replication competent plasmids of hepatitis B virus subgenotypes A1, A2 and D3 with authentic endogenous promoters.

  2014cites this paper
• rtM204Q May Serve as a Novel Lamivudine-Resistance-Associated Mutation of Hepatitis B Virus

  2014cites this paper
• The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies

  2013cites this paper
• Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line.

  2013influential citation
• Comprehensive analysis of Hepatitis B virus antiviral drug resistance mutations based on a new high-throughput phenotypic assay

  2013cites this paper
• Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B

  2012cites this paper
• The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.

  2012cites this paper
• Management of treatment failure in chronic hepatitis B.

  2012cites this paper
• Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients.

  2011cites this paper
• Update on HBV Treatment and Management of Antiviral Resistance

  2011cites this paper
• Host factors may influence response to antiviral therapy in chronic hepatitis B virus infections.

  2011cites this paper
• Hepatitis B virus Resistance to Antivirals : Diagnosis and Management

  2011cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Kosteneffectiviteit van antivirale behandeling voor chronische hepatitis B in België

  2010cites this paper
• Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium

  2010cites this paper
• Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop

  2010cites this paper
• Viral Resistance in Hepatitis B: Prevalence and Management

  2010cites this paper
• Hepatitis B resistance in Iran.

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Viral Phenotypic Resistance Assays

  2009cites this paper
• Management and prevention of drug resistance in chronic hepatitis B

  2009cites this paper
• Pathobiology of HBV mutants and clinical impact for treatment monitoring

  2009cites this paper
• A new strategy for constructing in vitro replication-competent 1.3 copies of hepatitis B virus genome.

  2009cites this paper
• REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY

  2009cites this paper
• Hepatitis B virus resistance to nucleos(t)ide analogues.

  2009cites this paper
• Virología molecular del virus de la hepatitis B

  2008cites this paper
• Review: Current status of antiviral therapy for hepatitis B

  2008cites this paper
• [Resistance in hepatitis B virus].

  2008cites this paper
• The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

  2008cites this paper
• Resistencias en el virus de la hepatitis B

  2008cites this paper
• [Molecular virology of the hepatitis B virus].

  2008cites this paper
• Chronic hepatitis B: preventing, detecting, and managing viral resistance.

  2008cites this paper
• Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?

  2008cites this paper
• Etude de la réplication du VHB et de la réponse à l'intracellulaire à l'infection virale

  2008cites this paper
• Management of hepatitis B: Summary of a clinical research workshop

  2007cites this paper
• Antiviral therapy of chronic hepatitis B: prevention of drug resistance.

  2007cites this paper
• Antiviral‐resistant hepatitis B virus: can we prevent this monster from growing?

  2007cites this paper
• Current and future therapies for chronic HBV-infections

  2007cites this paper
• Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

  2007cites this paper
• Hepatitis B Virus Drug Resistance and Combination Therapy

  2007cites this paper
• Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

  2007cites this paper
• Emerging drugs for hepatitis B

  2007cites this paper
• Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines.

  2007cites this paper
• Immunopathogenesis: Role of Innate and Adaptive Immune Responses

  2006cites this paper
• Antiviral Drug Resistance: Clinical Consequences and Molecular Aspects

  2006cites this paper
• New nucleic acid diagnostic tests in viral hepatitis.

  2006cites this paper
• New Nucleic Acid Diagnostic Tests in Viral Hepatitis

  2006cites this paper
• [Hepatitis B and C virus antiviral resistance].

  2006cites this paper
• HepSEQ: International Public Health Repository for Hepatitis B

  2006cites this paper
• Resistencias a los antivirales en los virus de las hepatitis B y C

  2006cites this paper
• Antiviral drug resistance: clinical consequences and molecular aspects.

  2006cites this paper
• World Journal of Hepatology

  year unknowncites this paper